Cargando…
Management of patients with fibrosing interstitial lung diseases
PURPOSE: This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. SUMMARY: The interstitial lung diseases are a heterogenous group of parenchymal lung disorders wi...
Autores principales: | Morrow, Lee E, Hilleman, Daniel, Malesker, Mark A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881211/ https://www.ncbi.nlm.nih.gov/pubmed/34608488 http://dx.doi.org/10.1093/ajhp/zxab375 |
Ejemplares similares
-
Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019) -
A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
por: Hilleman, Daniel E, et al.
Publicado: (2009) -
Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020) -
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
por: Richeldi, Luca, et al.
Publicado: (2018) -
Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)